<DOC>
	<DOCNO>NCT01780181</DOCNO>
	<brief_summary>The purpose study observe efficacy chemotherapy combine Traditional Chinese Medicine elderly patient advance non-small-cell lung cancer , also evaluate adverse reaction reliability .</brief_summary>
	<brief_title>Clinical Study Chemotherapy Combined With Chinese Medicine Survival Affect Elderly Patients With Lung Cancer</brief_title>
	<detailed_description>Non-small-cell lung cancer ( NSCLC ) account approximately 80 % lung cancer diagnose 75 % patient diagnose advanced stage . ASCO guideline recommend elderly patient advance NSCLC use single-agent chemotherapy . Nearly decade clinical trial show : median survival time ( MST ) Vinorelbine 5-10months,1-year survival rate 32 % ; MST Gemcitabine 6.8-9months , MST Taxol 6.8-10.3months.Research show TCM prolong long-term survival improve QOL , high-level evidence desperately need support finding . The investigator perform multi-center , randomize , double-blind control , prospective study elderly patient advance NSCLC . Patients randomize observational group ( TCM granules plus single-agent chemotherapy ) , control group ( TCM placebo plus single-agent chemotherapy ) . The investigator observe 4 cycle regular follow-up arrange . The primary end point : PFS ( progression-free survival ) ; secondary end point : ( 1 ) OS ( overall survival ) ; ( 2 ) Objective response rate ; ( 3 ) TTP ( Time-to-Progression ) ; ( 4 ) QOL ( EORTC QLQ-L43 , TCM syndrome score ) ; ( 5 ) end point : Toxicity , side effect security treatment assess time . The investigator expect integrate TCM combine chemotherapy well efficacy prolong PFS , OS , improve QOL , reduce adverse reaction patient chemotherapy.Therefore study provide evidence optimize promote integrate TCM combine Western Medicine treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Pathologically cytologically confirm stage IIIbIV NSCLC ; 2 . Ages Eligible Study : ≥65 year old ; 3 . Physical status score ( ECOG PS ) ≤ 2 score ; 4 . Estimated life expectancy least 12 week ; 5 . Participants major organ dysfunction chemotherapy contraindication : hemoglobin ≥9g/dL , absolute neutrophil count ( ANC ) ≥1.5*109/L , platelet ≥100 *109/L , bilirubin≤1.5ULN , alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤2.5 upper limited number ( ULN ) ( AP , AST , ALT ≤5ULN acceptable liver tumor involvement ) .INR≤1.5 , APTT normal range ( 1.2DLN1.2ULN ) , creatinine≤1.5ULN ; 6 . Informed consent patient . 1 . Patient malignant tumor except NSCLC 5 year previous study entry . 2 . Patients receive singleagent chemotherapy treatment； 3 . Estimated life expectancy le 12 week ; 4 . Serious problem heart , liver kidney severe dysfunction ; 5 . Pregnant child breast feeding woman ; 6 . Mental cognitive disorder ; 7 . Participating drug trial ; 8. Who allergic study drug .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>traditional Chinese medicine</keyword>
</DOC>